Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Michelle Dickens

Nurse Practitioner Springfield, MO Nurse Practitioner

NPI 1861506610 CMS profile 10897963

927 E Wayside Pl, Springfield, MO 65807

Open in the dashboard

General payments

$59,011

408 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Michelle Dickens of Springfield, MO is reported in the CMS Open Payments database as having received $59,011 across 408 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $9,332 45
2022 General $39,142 221
2021 General $10,537 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Dickens
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michelle Dickens were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michelle Dickens Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $10,537 $135 $40–$426 $132
2022 $39,142 $152 $48–$470 $149
2023 $9,332 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AstraZeneca Pharmaceuticals LP $54,445 170 payments
  2. GlaxoSmithKline, LLC. $643 42 payments
  3. Genzyme Corporation $587 18 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $493 26 payments
  5. CSL Behring $431 24 payments
  6. Pfizer Inc. $399 17 payments
  7. Amgen Inc. $322 15 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $258 17 payments
  9. Genentech USA, Inc. $213 15 payments
  10. Blueprint Medicines Corporation $203 6 payments
  11. Other $1,017 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $39,150 27 payments
  2. Food and Beverage $8,536 345 payments
  3. Travel and Lodging $7,244 30 payments
  4. Consulting Fee $4,060 2 payments
  5. Education $21 4 payments
Products named General payments · program years 2021–2023
  1. FASENRA $21,216 75 payments
  2. TEZSPIRE Respiratory $16,872 40 payments
  3. DUPIXENT $1,070 40 payments
  4. NUCALA $455 27 payments
  5. BREZTRI $415 17 payments
  6. TAKHZYRO $406 22 payments
  7. SPIRIVA RESPIMAT $325 21 payments
  8. TEZSPIRE Inflammation $310 14 payments
  9. Haegarda $289 16 payments
  10. Xolair $283 15 payments
  11. Other $2,310 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

408 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record